Nothing Special   »   [go: up one dir, main page]

PT786998E - A utilizacao de ¬r-(z)|-alfa-(metoxiimino)-alfa-(1-azabiciclo-¬2.2.2|-oct-3-il) acetonitrilo para reduzir a formacao de beta amiloide a4 na doenca de alzheimer - Google Patents

A utilizacao de ¬r-(z)|-alfa-(metoxiimino)-alfa-(1-azabiciclo-¬2.2.2|-oct-3-il) acetonitrilo para reduzir a formacao de beta amiloide a4 na doenca de alzheimer

Info

Publication number
PT786998E
PT786998E PT95936515T PT95936515T PT786998E PT 786998 E PT786998 E PT 786998E PT 95936515 T PT95936515 T PT 95936515T PT 95936515 T PT95936515 T PT 95936515T PT 786998 E PT786998 E PT 786998E
Authority
PT
Portugal
Prior art keywords
alfa
alzheimer
disease
pct
oct
Prior art date
Application number
PT95936515T
Other languages
English (en)
Inventor
Roger Edward Markwell
Julie Hawkins
Carol W Gray
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PT786998E publication Critical patent/PT786998E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT95936515T 1994-10-25 1995-10-17 A utilizacao de ¬r-(z)|-alfa-(metoxiimino)-alfa-(1-azabiciclo-¬2.2.2|-oct-3-il) acetonitrilo para reduzir a formacao de beta amiloide a4 na doenca de alzheimer PT786998E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9421472A GB9421472D0 (en) 1994-10-25 1994-10-25 Novel methods

Publications (1)

Publication Number Publication Date
PT786998E true PT786998E (pt) 2002-09-30

Family

ID=10763350

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95936515T PT786998E (pt) 1994-10-25 1995-10-17 A utilizacao de ¬r-(z)|-alfa-(metoxiimino)-alfa-(1-azabiciclo-¬2.2.2|-oct-3-il) acetonitrilo para reduzir a formacao de beta amiloide a4 na doenca de alzheimer

Country Status (22)

Country Link
US (1) US5891887A (pt)
EP (1) EP0786998B1 (pt)
JP (1) JPH10509697A (pt)
KR (1) KR100393365B1 (pt)
CN (1) CN1085529C (pt)
AT (1) ATE214926T1 (pt)
AU (1) AU698695B2 (pt)
BG (1) BG101500A (pt)
BR (1) BR9509433A (pt)
CZ (1) CZ287370B6 (pt)
DE (1) DE69526102T2 (pt)
DK (1) DK0786998T3 (pt)
ES (1) ES2173977T3 (pt)
GB (1) GB9421472D0 (pt)
HK (1) HK1002057A1 (pt)
HU (1) HUT77007A (pt)
NO (1) NO312055B1 (pt)
NZ (1) NZ295155A (pt)
PT (1) PT786998E (pt)
SK (1) SK50497A3 (pt)
WO (1) WO1996012486A1 (pt)
ZA (1) ZA958946B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751607B2 (en) * 1995-07-29 2002-08-22 Smithkline Beecham Plc Method of treatment of dementia
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
JP2002506031A (ja) 1998-03-11 2002-02-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 組成物
GB9815383D0 (en) * 1998-07-15 1998-09-16 Smithkline Beecham Plc Novel method of treatment
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US7816149B2 (en) * 2004-03-29 2010-10-19 Applied Photonics Worldwide, Inc. Nanobioprocessor for protein and cell therapy
GB0428170D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2219636T3 (es) * 1989-04-13 2004-12-01 Beecham Group P.L.C. Nuevos compuestos.
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
MX9300875A (es) * 1992-02-20 1993-08-31 Smithkline Beecham Plc Procedimiento para la preparacion de compuestos azabiciclicos.
WO1994009370A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
GB9409705D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
KR100393365B1 (ko) 2003-12-18
WO1996012486A1 (en) 1996-05-02
NO971899D0 (no) 1997-04-24
US5891887A (en) 1999-04-06
GB9421472D0 (en) 1994-12-07
DK0786998T3 (da) 2002-07-15
EP0786998A1 (en) 1997-08-06
ZA958946B (en) 1996-08-20
AU698695B2 (en) 1998-11-05
CZ287370B6 (en) 2000-11-15
BG101500A (en) 1998-01-30
HK1002057A1 (en) 1998-07-31
BR9509433A (pt) 1997-09-16
NZ295155A (en) 2000-07-28
DE69526102T2 (de) 2002-10-31
CN1085529C (zh) 2002-05-29
CZ125197A3 (en) 1997-07-16
SK50497A3 (en) 1997-09-10
JPH10509697A (ja) 1998-09-22
KR970706816A (ko) 1997-12-01
NO312055B1 (no) 2002-03-11
DE69526102D1 (de) 2002-05-02
HUT77007A (hu) 1998-03-02
MX9703077A (es) 1997-07-31
CN1170365A (zh) 1998-01-14
AU3843195A (en) 1996-05-15
EP0786998B1 (en) 2002-03-27
NO971899L (no) 1997-04-24
ES2173977T3 (es) 2002-11-01
ATE214926T1 (de) 2002-04-15

Similar Documents

Publication Publication Date Title
EA200501023A1 (ru) Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BR0010498A (pt) Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
BR0315283A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de doenças neurológicas ou de doenças inflamatórias do trato respiratório superior
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
PT840601E (pt) Thip para o tratamento de desordens do sono
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
AR024074A1 (es) FRAGMENTO ABETA UNIDO A UN PÉPTIDO PORTADOR PARA PREVENIR O TRATAR ENFERMEDADES ASOCIADAS CON DEPoSITOS AMILOIDES DE ABETA, COMPOSICIONES FARMACÉUTICAS QUE LO CONTIENEN, Y SU USO EN LA PREPARACION DE MEDICAMENTOS.
BRPI0408256A (pt) composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
HK1076379A1 (en) Use of a composition comprising anti-vla-1 antibody for the preparation of a pharmaceutical composition for the treatment of pulmonary fibrosis
BR9916860A (pt) Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
GEP20053423B (en) Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits
PT786998E (pt) A utilizacao de ¬r-(z)|-alfa-(metoxiimino)-alfa-(1-azabiciclo-¬2.2.2|-oct-3-il) acetonitrilo para reduzir a formacao de beta amiloide a4 na doenca de alzheimer
HUP0202525A2 (hu) Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit
DK0738147T3 (da) Anvendelse af riluzol ved behandling af mitochondriesygdomme
SE8903529D0 (sv) Medical use
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR0211358A (pt) Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
BRPI0409387A (pt) método para o tratamento de doença de tecido mole em um indivìduo mamìfero, composição farmacêutica, complexo de alvejamento de tecido mole, método para a formação de um complexo, e, kit para uso em um método
TR200103561T2 (tr) Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları
KR930703013A (ko) 항당뇨병제로서 유용한 신규한 글루코하이드롤라제 억제제
DK0642338T3 (da) Anvendelse af (E)-2-(p-fluorphenethyl)-3-fluorallylamin i behandlingen af Alzheimers sygdom